We report our experience over the last seventeen years (1985-2002) of the treatment of acute lymphoblastic leukemia (ALL) in children at the University of Liege Pediatric Department of Hematogy-Oncology (CHU-Sart Tilman and CHR-Citadelle). Seventy seven children are enrolled in our study; the mean follow-up is 6.7 years. The 5 years over all survival and the disease free survival for the entire group are respectively 83% and 79%. Prognostic factors shown in our study are sex, high white blood cells counts at diagnosis and immunophenotypes.